BMEA
Biomea Fusion, Inc. NASDAQ Listed Apr 16, 2021$1.63
Mkt Cap $97.0M
52w Low $0.87
34.3% of range
52w High $3.08
50d MA $1.53
200d MA $1.52
P/E (TTM)
-1.2x
EV/EBITDA
-0.1x
P/B
2.4x
Debt/Equity
0.1x
ROE
-209.1%
P/FCF
-0.9x
RSI (14)
—
ATR (14)
—
Beta
-0.27
50d MA
$1.53
200d MA
$1.52
Avg Volume
1.4M
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.
900 Middlefield Road · Redwood City, CA 94063 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 24, 2026 | AMC | -0.25 | -0.64 | -156.0% | 1.13 | +0.9% | +8.0% | +21.2% | +16.8% | +16.8% | +35.4% | — |
| Nov 4, 2025 | AMC | -0.26 | -0.27 | -3.8% | 1.26 | -0.8% | +6.3% | +3.2% | +8.7% | +8.7% | +11.1% | — |
| Aug 5, 2025 | AMC | -0.59 | -0.51 | +13.6% | 1.58 | +1.9% | +0.6% | +3.2% | -2.5% | -3.2% | +4.4% | — |
| May 5, 2025 | AMC | -0.84 | -0.80 | +4.8% | 2.00 | -4.0% | -16.5% | -15.0% | -12.5% | -18.5% | -11.5% | — |
| Mar 31, 2025 | AMC | -1.00 | -0.81 | +19.0% | 2.13 | +5.2% | -6.6% | +1.4% | -8.5% | -0.5% | -5.6% | — |
| Oct 29, 2024 | AMC | -1.05 | -0.91 | +13.3% | 12.06 | +1.0% | -14.3% | -22.3% | -25.0% | -26.7% | -26.1% | — |
| Jul 31, 2024 | AMC | -1.03 | -1.03 | +0.0% | 5.57 | +6.6% | +3.2% | +2.3% | +1.8% | +9.5% | +3.6% | — |
| May 2, 2024 | AMC | -1.02 | -1.09 | -6.9% | 11.93 | +7.5% | +3.5% | +2.8% | +0.6% | -7.2% | -4.1% | — |
| Apr 1, 2024 | AMC | -0.85 | -0.98 | -15.3% | 15.30 | -9.9% | -16.3% | -8.8% | -17.6% | -16.8% | -18.2% | — |
| Oct 30, 2023 | AMC | -0.83 | -0.80 | +3.6% | 11.06 | -7.3% | -7.6% | -5.5% | -9.0% | -8.8% | -16.3% | — |
| Jul 31, 2023 | AMC | -0.86 | -0.70 | +18.6% | 22.25 | +0.3% | -6.7% | -13.7% | -14.7% | -13.2% | -17.8% | — |
| May 2, 2023 | AMC | -0.80 | -0.98 | -22.5% | 29.00 | +3.1% | +5.8% | +10.4% | +12.1% | +15.0% | +16.3% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 28 | D. Boral Capital | Maintains | Buy → Buy | — | $1.73 | $1.72 | -0.6% | -11.6% | -15.6% | -21.4% | -20.8% | -14.5% |
| Apr 8 | D. Boral Capital | Maintains | Buy → Buy | — | $1.90 | $1.90 | +0.0% | -7.4% | -2.6% | -1.6% | -1.1% | +2.6% |
| Mar 27 | Citigroup | Maintains | Buy → Buy | — | $1.37 | $1.36 | -0.7% | -3.6% | -3.6% | +11.7% | +8.8% | +12.4% |
| Mar 25 | D. Boral Capital | Maintains | Buy → Buy | — | $1.13 | $1.14 | +0.9% | +8.0% | +21.2% | +16.8% | +16.8% | +35.4% |
| Jan 13 | D. Boral Capital | Maintains | Buy → Buy | — | $1.46 | $1.52 | +4.1% | +4.1% | +11.0% | -4.1% | -3.4% | -5.5% |
| Nov 10 | Citigroup | Maintains | Buy → Buy | — | $1.37 | $1.40 | +2.2% | +0.0% | +2.2% | +0.0% | -5.8% | -6.6% |
| Nov 5 | D. Boral Capital | Maintains | Buy → Buy | — | $1.26 | $1.25 | -0.8% | +6.3% | +3.2% | +8.7% | +8.7% | +11.1% |
| Oct 27 | D. Boral Capital | Maintains | Buy → Buy | — | $1.46 | $1.48 | +1.4% | -2.7% | -5.5% | -6.2% | -8.9% | -6.8% |
| Oct 7 | D. Boral Capital | Maintains | Buy → Buy | — | $2.67 | $1.98 | -25.8% | -30.7% | -37.1% | -33.0% | -37.1% | -38.2% |
| Oct 3 | D. Boral Capital | Maintains | Buy → Buy | — | $2.13 | $2.15 | +0.9% | +0.9% | +25.4% | -13.1% | -21.1% | -16.0% |
| Aug 11 | Citigroup | Maintains | Buy → Buy | — | $1.54 | $1.55 | +0.6% | -0.6% | +7.1% | +11.7% | +9.7% | +12.3% |
| Aug 6 | Scotiabank | Maintains | Sector Outperform → Sector Outperform | — | $1.58 | $1.61 | +1.9% | +0.6% | +3.2% | -2.5% | -3.2% | +4.4% |
| Aug 6 | D. Boral Capital | Maintains | Buy → Buy | — | $1.58 | $1.61 | +1.9% | +0.6% | +3.2% | -2.5% | -3.2% | +4.4% |
| Jul 21 | D. Boral Capital | Maintains | Buy → Buy | — | $1.85 | $1.89 | +2.2% | -1.1% | -1.6% | +0.0% | -2.2% | -1.1% |
| Jul 16 | Citigroup | Maintains | Buy → Buy | — | $1.78 | $1.85 | +3.9% | +7.3% | +5.6% | +3.9% | +2.8% | +2.2% |
| Jun 24 | D. Boral Capital | Maintains | Buy → Buy | — | $1.69 | $1.77 | +4.7% | +11.2% | +14.8% | +17.8% | +7.1% | +6.5% |
| Jun 18 | D. Boral Capital | Maintains | Buy → Buy | — | $2.90 | $2.06 | -29.0% | -34.1% | -37.6% | -41.7% | -35.2% | -33.1% |
| Jun 13 | D. Boral Capital | Maintains | Buy → Buy | — | $2.61 | $2.57 | -1.5% | -9.6% | +0.8% | +11.1% | -26.8% | -30.7% |
| May 15 | D. Boral Capital | Maintains | Buy → Buy | — | $1.46 | $1.46 | +0.0% | -2.1% | +4.1% | +3.4% | +7.5% | -0.7% |
| May 6 | D. Boral Capital | Maintains | Buy → Buy | — | $2.00 | $1.92 | -4.0% | -16.5% | -15.0% | -12.5% | -18.5% | -11.5% |
| May 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.00 | $1.92 | -4.0% | -16.5% | -15.0% | -12.5% | -18.5% | -11.5% |
| Apr 2 | Barclays | Maintains | Equal Weight → Equal Weight | — | $1.99 | $1.94 | -2.5% | +8.5% | -2.0% | +6.5% | +1.0% | -14.1% |
| Apr 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.13 | $2.24 | +5.2% | -6.6% | +1.4% | -8.5% | -0.5% | -5.6% |
| Mar 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.30 | $2.25 | -2.2% | -7.4% | -13.5% | -6.1% | -15.2% | -7.8% |
| Mar 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.79 | $2.82 | +1.1% | -3.6% | -9.7% | -10.8% | -17.6% | -23.7% |
| Mar 24 | D. Boral Capital | Maintains | Buy → Buy | — | $2.87 | $3.00 | +4.5% | -2.8% | -6.3% | -12.2% | -13.2% | -19.9% |
| Mar 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.87 | $3.00 | +4.5% | -2.8% | -6.3% | -12.2% | -13.2% | -19.9% |
| Mar 19 | D. Boral Capital | Maintains | Buy → Buy | — | $2.53 | $2.55 | +0.8% | +7.9% | +9.5% | +13.4% | +10.3% | +6.3% |
| Jan 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.06 | $4.17 | +2.7% | +0.0% | -2.0% | +4.7% | +6.4% | +10.3% |
| Jan 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.15 | $4.15 | +0.0% | +0.0% | -2.2% | -2.2% | -4.1% | +2.4% |
| Jan 13 | D. Boral Capital | Maintains | Buy → Buy | — | $3.98 | $3.84 | -3.5% | +4.3% | +4.3% | +2.0% | +2.0% | +0.0% |
| Jan 10 | D. Boral Capital | Maintains | Buy → Buy | — | $4.27 | $4.21 | -1.4% | -6.8% | -2.8% | -2.8% | -4.9% | -4.9% |
| Dec 19 | D. Boral Capital | Maintains | Buy → Buy | — | $3.88 | $4.02 | +3.6% | +5.2% | +9.0% | +3.9% | +3.4% | +5.2% |
| Dec 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.64 | $4.62 | -0.4% | -16.4% | -12.1% | -8.8% | -13.1% | -13.6% |
| Dec 17 | D. Boral Capital | Maintains | Buy → Buy | — | $5.85 | $5.21 | -10.9% | -20.7% | -33.7% | -30.3% | -27.7% | -31.1% |
| Dec 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.64 | $5.69 | +0.9% | +3.7% | -17.7% | -31.2% | -27.7% | -25.0% |
| Dec 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.79 | $5.85 | +1.0% | -0.5% | +6.0% | +0.2% | -2.6% | +1.0% |
| Dec 10 | D. Boral Capital | Maintains | Buy → Buy | — | $5.79 | $5.85 | +1.0% | -0.5% | +6.0% | +0.2% | -2.6% | +1.0% |
| Nov 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.28 | $6.28 | +0.0% | +1.6% | +2.5% | +10.4% | +9.7% | +11.8% |
| Nov 19 | D. Boral Capital | Maintains | Buy → Buy | — | $6.43 | $6.45 | +0.3% | -0.2% | -2.3% | -0.8% | +0.2% | +7.8% |
| Oct 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.34 | $10.46 | +1.2% | -9.4% | -12.6% | -14.5% | -13.8% | -14.1% |
| Oct 31 | Piper Sandler | Maintains | Overweight → Overweight | — | $10.34 | $10.46 | +1.2% | -9.4% | -12.6% | -14.5% | -13.8% | -14.1% |
| Oct 31 | EF Hutton | Maintains | Buy → Buy | — | $10.34 | $10.46 | +1.2% | -9.4% | -12.6% | -14.5% | -13.8% | -14.1% |
| Oct 30 | Barclays | Maintains | Equal Weight → Equal Weight | — | $12.06 | $12.18 | +1.0% | -14.3% | -22.3% | -25.0% | -26.7% | -26.1% |
| Oct 30 | EF Hutton | Maintains | Buy → Buy | — | $12.06 | $12.18 | +1.0% | -14.3% | -22.3% | -25.0% | -26.7% | -26.1% |
| Oct 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.24 | $11.25 | +0.1% | +2.0% | +0.6% | +2.8% | +8.1% | +10.4% |
| Oct 22 | HC Wainwright& Co. | Maintains | Buy → Buy | — | $11.24 | $11.25 | +0.1% | +2.0% | +0.6% | +2.8% | +8.1% | +10.4% |
| Sep 27 | Truist | Upgrade | Hold → Buy | — | $9.57 | $11.48 | +20.0% | +3.4% | +5.5% | -0.7% | +5.9% | +5.4% |
| Sep 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.57 | $11.48 | +20.0% | +3.4% | +5.5% | -0.7% | +5.9% | +5.4% |
| Sep 27 | Barclays | Maintains | Equal Weight → Equal Weight | — | $9.57 | $11.48 | +20.0% | +3.4% | +5.5% | -0.7% | +5.9% | +5.4% |
No insider trades available.
8-K · 7.01
! Medium
Biomea Fusion, Inc. -- 8-K 7.01: Regulation FD Disclosure
Biomea Fusion furnished investor presentation slides for an upcoming call, signaling management intends to communicate updates on company strategy or performance directly to shareholders.
Apr 28
8-K
Unknown — 8-K Filing
Biomea's lead diabetes drug showed sustained benefits months after short treatment, potentially supporting a valuable therapeutic approach that could drive near-term clinical advancement and investor confidence.
Mar 24
8-K · 7.01
! Medium
Biomea Fusion, Inc. -- 8-K 7.01: Regulation FD Disclosure
Biomea Fusion disclosed a corporate presentation to investors via their website, providing updated company information for stakeholder review.
Feb 25
Data updated apr 24, 2026 10:09pm
· Source: massive.com